miRagen’s Director of Biology to Give Keynote Lecture at The Ohio State University College of Pharmacy’s Research Day & Symposium

Presentation to focus on targeting microRNAs implicated in heart disease as a strategy for therapeutic intervention

BOULDER, CO, May 25, 2010 – miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today that its Director of Biology, Eva van Rooij, Ph.D., will give the keynote lecture at The Ohio State University College of Pharmacy’s Research Day & Symposium. The lecture, which is scheduled to take place this afternoon in the University’s Biomedical Research Tower, will center on miRNAs of interest to miRagen and the chemistries involved in their manipulation.

“Our data demonstrate that specific microRNAs play important roles in adverse cardiac events experienced in heart disease,” said William S. Marshall, Ph.D., President and CEO of miRagen Therapeutics, Inc. “Dr. van Rooij will present data that illustrate our ability to manipulate the level of miRNAs in the heart in multiple disease models with compelling results. We are pleased to share our findings—not only to spark interest in the field of microRNA biology among the researchers of tomorrow, but also for the hope it offers to patients in an area of such high unmet medical need.”

About microRNAs: MicroRNAs have emerged as an important class of small RNAs encoded in the genome. They act to control the expression of sets of genes and entire pathways and are thus thought of as master regulators of gene expression. Recent studies have demonstrated that microRNAs are responsible for many diseases. Because they are single molecular entities that dictate the expression of fundamental regulatory pathways, microRNAs represent potential drug targets of unprecedented power.

About miRagen Therapeutics: miRagen Therapeutics, Inc., was founded in 2007 to develop innovative microRNA-based therapeutics for cardiovascular and muscle disease. Only recently discovered, microRNAs are short, single-stranded RNA molecules encoded in the genome that regulate gene expression and play a vital role in influencing cardiovascular and muscle disease. Cardiovascular disease is the leading cause of death globally and represents an enormous burden on global healthcare systems. Principally funded through venture capital investments, miRagen combines world recognized leadership in cardiovascular medicine with unprecedented in-house expertise in microRNA biology and chemistry. For more information, please visit www.miragentherapeutics.com.